<DOC>
	<DOC>NCT00005931</DOC>
	<brief_summary>The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).</brief_summary>
	<brief_title>SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment</brief_title>
	<detailed_description>Patients are given SU5416 via twice-weekly intravenous infusions in 4-week treatment cycles. Any patient who has not experienced unacceptable toxicity and who is deemed to be responding to the study drug (no evidence of disease progression) is permitted to continue receiving SU5416 in 4-week treatment cycles (up to a maximum of 1 year of therapy) until that patient experiences either unacceptable toxicity or tumor progression, as defined in the protocol.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma, Kaposi</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>Inclusion Criteria Patients may be eligible for this study if they: Are at least 18 years old. Have KS. Have taken paclitaxel, DaunoXome, or Doxil for KS and they have either not gotten better or could not tolerate treatment therapy. Have 1 of the following symptoms for KS: 5 lesions (sores), generalized KSrelated edema (swelling) without sores, or KSrelated edema of the arms and legs. Agree to use an effective method of birth control during the study. Exclusion Criteria Patients will not be eligible for this study if they: Are pregnant or breastfeeding. Are allergic to Cremophor.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2000</verification_date>
	<keyword>Skin Neoplasms</keyword>
	<keyword>Sarcoma, Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antineoplastic Agents</keyword>
	<keyword>Enzyme Inhibitors</keyword>
	<keyword>SU 5416</keyword>
	<keyword>Protein-Tyrosine Kinase</keyword>
</DOC>